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Lower respiratory tract infections are common in the adult
population, with an estimated incidence of approximately
44% (1). This high incidence rate signifies that clinicians are
daily called to face a disease that may become extremely
threatening if not adequately treated. Unfortunately,
treatment of respiratory infections is a complex and
continuously evolving process. The emergence of new
pathogens, variations in antibiotic susceptibility among
traditional pathogens, and the ever-increasing presence of
complex immunocompromised patients at high risk for the
development of severe lower respiratory tract infections
determine the need for continual modification of the
treatment schemes in use. Open problems such as the
clinical utility of distinguishing between typical and atypical
pneumonia, doubts concerning antibiotic treatment in the
elderly and the validity of antibiotic associations, are as yet
unresolved due to the size, complexity and expense of the
studies that would be required to give definitive answers.
This further complicates the decision-making processes that
are complex enough in the first place (2).
Although beset by the diculties arising from several
therapeutic uncertainties, the clinician must nonetheless
deal with newly arising socioeconomical contingencies. We
are now entering an era in health management in which
clinicians no longer take treatment decisions on the basis of
scientific reasoning alone, but predominantly based on
economical considerations. In practice, the clinician must
reduce the cost of therapy, or at least slow its growth, while
still maintaining the clinical ecacy of treatment with more
expensive and often more innovative drugs.
The clinical complexity associated with infectious dis-
eases and the call for a reduction in health expenses have
urged scientific societies to develop guidelines to assist
clinicians in the management of lower respiratory tract
bacterial infections. Practice guidelines have the opportu-
nity to support primary care physician decision-making byReceived 15 November 1999 and accepted in revised form 4 August
2000.
Correspondence should be addressed to: M. Cazzola, Via del Parco
Margherita 24, 80121 Napoli, Italy. Fax: +39 0817473331; E-mail:
mcazzola@qubisoft.it
0954-6111/01/020095+14 $35?00/0providing current treatment and triage recommendations at
the time of patient encounter.
Guidelines for the management of
acute exacerbations of chronic
bronchitis
It must be stressed that exacerbations of chronic bronchitis
are generally inadequately discussed in most currently
available guidelines [American Thoracic Society (ATS) (3),
European Respiratory Society (ERS) (4) and British
Thoracic Society (BTS) (5)]. This is probably because
current guidelines are generally focused on the overall
management of COPD. The only document which specifi-
cally focuses on acute exacerbations of chronic bronchitis is
the Canadian guideline (Table 1) (6).
The reluctance in addressing this aspect in a more
thorough manner is certainly justified by the strong
controversy surrounding the role of antibiotic treatment
in acute exacerbations of chronic bronchitis (AECB) (7).
The decision to prescribe antibiotics in patients with an
AECB has been debated in the literature (8–19). Many
studies have shown either no benefit, or minimal benefit,
when antibiotics are prescribed for an AECB. A recent
study conducted in Great Britain showed that patients
recover from exacerbations irrespective of treatment
employed, except when past history reveals co-existent
cardiopulmonary diseases or frequent exacerbations (20).
On the other hand, Murphy and Sethi (21) suggested that
most infectious events in chronic bronchitis are sponta-
neously resolving processes involving the mucosal lining
alone, that need no treatment.
In effect, the role of infection in exacerbations of chronic
bronchitis remains controversial and incompletely under-
stood. Some investigators believe that bacteria are not
important for patients with exacerbation (22). However,
when strictly defined by application of several newer
investigative techniques, it is likely that 80% of AECB
are infectious in origin, with 40–50% caused by
bacteria, 30% by viruses and 5–10% by atypical
bacteria (23). Concomitant infections by more than one
infectious pathogen appear to occur in 10–20% of patients.# 2001 HARCOURT PUBLISHERS LTD
TABLE 1. Canadian guidelines for the treatment of chronic bronchitis exacerbations (6)
Bacteria involved Streptococcus, Haemophilus, Moraxella; rise in resistant strains
When to treat two of the following: increase in sputum/cough, sputum purulence, dyspnoea
Initial antibiotics Aminopenicillin, tetracyclines, co-trimoxazole
Secondary antibiotics 2nd or 3rd generation cephalosporins, co-amoxiclav, new macrolides, quinolones
TABLE 2. European guidelines (ESOCAP) for the treatment of chronic bronchitis exacerbations (31)
Bacteria involved Streptococcus, Haemophilus, Moraxella; Staphylococcus and resistant strains are on the increase
When to treat Increase in dyspnoea, increased sputum volume and purulence during exacerbations
Initial antibiotics
Secondary antibiotics
Amoxicillin, co-amoxiclav
Macrolides (azithromycin or clarithromycin),
fluoroquinolones (ofloxacin or ciprofloxacin),
cefuroxime axetil, pristinamycin, doxicycline
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parainfluenzae, and Moraxella catarrhalis are the bacteria
primarily incriminated. However, Enterobacteriaceae and
Pseudomonas aeruginosa are isolated more frequently than
other organisms and should be taken into account in
infective exacerbations of patients with severe disease, as
reflected by low levels of FEV1, deeper hypoxaemia,
malnutrition and more frequent hospitalizations (24,25).
In any case, even when clinical deterioration is caused by
infection, identification of the causal organism is often
dicult (26). Although the initial insult causing increased
cough and expectoration is probably viral in origin (27),
bacterial invasion may be demonstrated in many patients,
in addition to cases where viral exacerbations are compli-
cated by secondary bacterial infections (28).
Murphy et al. (29) think that the available data about
antibiotic therapy for exacerbations of COPD support a
role for their use, probably because bacteria are often
responsible for exacerbations. Several studies confirm this
opinion. The study by Anthonisen et al. (14) showed a
definite benefit for antibiotics in 480% of patients with
chronic bronchitis with exacerbations who had at least two
of the following three cardinal symptoms: increased
dyspnoea, increased sputum volume and increased sputum
purulence. The benefits of antibiotics were more dramatic
for patients with all three symptoms than for those with two
symptoms, but the benefits included more antibiotic treated
patients who responded to therapy than those who did not,
compared to placebo-treated patients. Moreover, a recent
meta-analysis (16) investigation revealed that antibiotic
treatment is associated with a modest but significant benefit
in patients with AECB that is clinically most relevant in
patients with severe underlying functional impairment. We
are confident that antibiotic treatment will continue to be
used in the future because there is a subset of patients that
does not spontaneously remit from the exacerbation (30). A
priori identification of this subset of patients is impossible.
The recommendations of ERS (4) move along these lines:
the need for exacerbation severity and functional impair-
ment assessment is beginning to break through. Antibiotictherapy is always recommended in severe exacerbations,
but also in non-severe exacerbations if an increase in
sputum purulence and volume are present together with
worsening dyspnoea.
According to the British school of thought (5), older
antibiotics are usually effective, whereas more recent drugs
are rarely appropriate. For this reason, amoxicillin and
tetracycline are considered first-choice agents in the U.K.,
unless previously shown to be ineffective. For more severe
exacerbations, or in case of lack of response to the above-
mentioned agents, second-line alternatives may be taken
into consideration, such as broad spectrum cephalosporins
or a recent macrolide.
The ATS guidelines (3) suggest a broader choice of
agents as first-line treatment, including tetracyclines,
erythromycin, co-trimoxazole, doxicycline, amoxicillin
and cefaclor. Broad spectrum penicillins and cephalospor-
ins are recommended alternative antibiotics.
European (4) and Canadian (6) guidelines suggest that
less expensive antibiotics are sucient, and recommend
amoxicillin and tetracycline derivative as initial antibiotics.
However, Europeans have recently suggested co-amoxiclav
as first-choice treatment, and macrolides, new cephalospor-
ins and fluoroquinolones as alternative antibiotics (Table 2)
(31). On the contrary, the Canadian guidelines (13) advise
that patients presenting a poor initial response should be
treated with a same antibiotics that the ATS (10) indicates
as alternative antibiotics, but go on to suggest that these
agents may be considered as appropriate first-choice drugs
in complicated cases: age 465 years, FEV1550% of
predicted, significant co-morbidity, multiple exacerbations
during the previous year.
The recommendations of the different guidelines appear
too generic and often are not the most economical. In fact,
even though the proposed antibiotics are generally effective
in individual cases and are scarcely expensive, they seldom
guarantee an optimal cost-effectiveness ratio. The impact
on the cost of treatment differs widely according to the
antibiotic employed, although drug costs never account for
more than 10–16% of total costs. The rate of relapse
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nant of costs, because patients with more relapses use more
health resources. On the other hand, slow remission of an
exacerbation also expands total treatment costs.
Comparing the time span between one exacerbation and
the next after the use of the so-called first-choice
(amoxicillin, tetracycline, erythromycin or co-trimoxazole),
second-choice (oral cephalosporins), or third-choice anti-
biotics (co-amoxiclav, ciprofloxacin and azithromycin), it
has been shown that first and second line drugs allow
exacerbation-free intervals of 18?3 and 23?7 weeks, respec-
tively, whereas third choice antibiotics gave an interval of
33 weeks (32).
Recently, Grossman et al. (33) evaluated costs, con-
sequences, ecacy and tolerability of ciprofloxacin
compared to traditional first-line antibiotics such as
amoxicillin, tetracycline, or co-trimoxazole in patients with
initial or recurrent exacerbations of chronic bronchitis over
a 1-year period. Treatment with ciprofloxacin tended to
hasten exacerbation remittal when compared to traditional
treatment; however, the differences were not statistically
significant. Apparently, data from the above study seem to
rule out the need for relatively recent antibiotics in the
treatment of patients with AECB. It must nonetheless be
pointed out that the same study showed that ciprofloxacin
was the most effective antibiotic in patients with four or
more exacerbations during the previous year.
This aspect is of extreme importance because it clearly
indicates that patient stratification into risk categories
allows the choice of optimal antibiotic therapy. This may
reduce the number of treatment failures and achieve the
selection of cost-effective options (34). However, a recent
paper by Dewan et al. (35) have demonstrated that patients
who had severe underlying lung disease and had greater
frequency and severity of exacerbation were more likely to
fail and the choice of an antibiotic did not affect the
treatment outcome. Nonetheless, current Canadian (6)
recommendations already include a stratification of risk
factors, limiting innovative drug use to highest risk patients.
Ball (36) also suggests limiting fluroroquinolones, new
macrolides and co-amoxiclav to patients belonging to stage
III of the scale, determined by a British study on AECB.
Stage III includes patients with acute exacerbation accom-
panied by dyspnoea and increase in sputum volume and
purulence, as well as co-morbidity and more than three or
four exacerbations a year. In these patients, resistant
organisms may co-exist with factors that inactivate anti-
biotics or reduce their penetration capacity. It is possible
that the selective use of newer antibiotics based on
stratification would also limit the emergence of drug-
resistant organisms.
Nevertheless, Adams et al. (37) have recently demon-
strated that relapse from AECB was not related to the
severity of underlying disease or to the severity of the acute
exacerbation. Patients treated with antibiotics had signifi-
cantly lower relapse rates than those who did not receive
antibiotics. However, the specific choice of antibiotic was
important because those treated with amoxicillin had the
highest relapse rates of all groups, which were probably
related to the increasing emergence of pathogen resistance.All the contrasting findings that are present in the
literature clearly show that the recommendations addres-
sing the management of AECB are over-simplified and do
not include risk factors predicting failure of initial
antimicrobial therapy. They are potentially useful for
treating patients with mild-to-moderate acute exacerba-
tions, but they do not consider that patients with more
advanced lung disease harbour different organisms and,
thus, may need a different therapy than patients with milder
disease. We trust that antibiotic treatment is an essential
action in most patients with AECB and an aggressive
approach to treatment of high-risk patients might improve
outcome. For this reason, we consider classification based
on a better understanding of risk factors and treatment
outcome with antibiotics proposed by Grossman (34) the
best present approach to the management of AECB (Table
3). The only criticism against this classification we have is
the lack of consideration for the potential presence of C.
pneumoniae and multi-drug-resistant S. pneumoniae
(DRSP). Since the newer fluoroquinolones (levofloxacin
and moxifloxacin) have a broad spectrum of action
covering these two pathogens and also multi-resistant H.
influenzae, we believe that their inclusion, at least for stages
II and III of Ball’s classification (20), is extremely useful.
Community-acquired pneumonia
guidelines
Guidelines on community-acquired pneumonia (CAP) have
been issued in many countries. Considering the guidelines
of four European countries (Table 4): Italy (38) France
(39), Spain (40) and Great Britain (41), it is evident that in
all cases indications are given for the management of two
patient groups: severe and non-severe. In particular, all the
above guidelines suggest the use of a penicillin or a
macrolide for non-severe patients because, although S.
pneumoniae remains the most common aetiological agent,
C. pneumoniae and Legionella pneumophila are also
important causes. There is no universally accepted defini-
tion for CAP severity but some factors are certainly
important (Table 5). If one or more of the conditions listed
in Table 5 are present, pneumonia is defined as severe. The
guidelines differ in recommending a penicillin or an
aminopenicillin, in suggesting single or combined use with
a macrolide, and in the routine prescription of a b-
lactamase inhibitor. Each document recommends the use
of an association between a second- or third-generation
cephalosporin and a macrolide in severe patients.
Although the above guidelines have apparently been
accepted by the scientific community, there are widely
differing antibiotic prescribing habits in general practi-
tioners in Western Europe (42). An analysis of the empirical
prescribing behaviour of European clinicians in the
treatment of CAP has shown that macrolides, aminopeni-
cillins with or without clavulanic acid and cephalosporins
are the most commonly used antibiotics, although the order
with which they are prescribed varies greatly among
different countries. Aminopenicillin was first or second
choice in four out of seven nations. Cephalosporin use was
very common in Germany and Southern Europe. In Italy,
TABLE 3. Proposed classification and antimicrobial treatment of bronchitis (34)
Baseline clinical
status
Criteria/risk factors Pathogens Treatment
I. Acute tracheobronchitis No underlying
structural disease;
acute cough and
sputum production
Usually viral None, for prolonged
symptoms consider
macrolide or
tetracycline
II. Simple chronic bronchitis FEV1450%, increased
sputum volume and
purulence, no
additional risk factors
H. influenzae,
Haemophilus spp.,
M. catarrhalis, S.
pneumoniae
Aminopenicillin
Tetracycline
Co-trimoxazole
III. Complicate chronic bronchitis Increased sputum
volume and purulence
þFEV1550%,
advanced age, 4
exacerbation/year
significant co-morbidity,
malnutrition, chronic
oral steriod usage
As for group II; Gram-
negatives more likely
in patients with FEV15
50%; resistance to b-
lactams common
Quinolone
b-lactam/b-lactamase
inhibitor-2nd or 3rd generation
cephalosporin
2nd generation
macrolide
IV. Chronic bronchial suppuration Continuous purulent
sputum production with
frequent exacerbations
As for group IIIþ
Enterobacteriaceae
and P. aeruginosa
Ciprofloxacin or other
i.v. antipseudomonas
agents
TABLE 4. Recommendations for initial empirical antibiotic treatment of community-acquired pneumonia (38–41)
Country Non-severe patient Severe patient
France Amoxicillin 1 g t.i.d. or macrolide Co-amoxiclavþ(macrolide or
fluoroquinolone) or 3rd generation
cephalosporinþ(macrolide or
fluoroquinolone)
Italy b-lactam/b-lactamase inhibitor+
macrolide
2nd/3rd generation cephalosporin +
macrolide
Spain Procaine penicillin 1,200,000 U b.i.d.
or erythromycin (ethylsuccinate) 2–4
g day71
3rd generation cephalosporinþ
erythromycin
Great Britain Aminopenicillin (amoxicillin 500mg
t.i.d. or benzyl-penicillin (1?2 g q.i.d.)
Erythromycinþ2nd or 3rd generation
cephalosporin or ampicillinþ
flucloxacillinþerythromycin
TABLE 5. Factors that allow the definition of community-
acquired pneumonia severity. Adapted from El-Ebiary
(106)
Respiratory rate 430 breaths min71
PaO2/FIO2 ratio 4250
Rapid radiographic worsening (50% increase in infiltrate
size within 48 h)
Bilateral or multi-lobar involvement
Shock
Need or vasopressors for more than 4 h
Evidence of sepsis with organ dysfunction
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imipenem was the most common choice (almost 40% of
cases). The differences in prescribing habits are certainly not
attributable to guidelines recommendations, nor can they be
explained by scientific reasoning, such as differences in
infection aetiology, penicillin-resistant pneumococcus rate,
pharmacokinetics and safety, and are not linked with
ecological or economical considerations. The differences are
presumably multi-factorial, and at least partly due to
diversities in local health systems (for example, in the U.K.
9% of patients with CAP are admitted to hospital, in contrast
to 2?5% in Spain, 2?7% in Germany and 5?1% in France)
(43) and to the sources of information at the clinician’s
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scientific rationale are probably equally important in the
empirical choice of the treatment for CAP (44).
The North American guidelines are more articulate
(45,46) including considerations on comorbidity, patient
age, disease severity, need for hospitalization and the
selection of one or more appropriate antimicrobial agents.
Specifically, the Canadian guidelines (45) divide non-severe
patients into those aged 565 years without comorbidity,
and those aged 65 years or more with comorbidity. Among
the former, macrolides are first-choice antibiotics, followed
by tetracyclines as second-line treatment. In patients with
comorbidity, second generation cephalosporins or a
combination of b-lactam/b-lactamase inhibitor, or co-
trimoxazole are recommended treatment choices. Macro-
lides may be added as an option to each of the above drugs,
Severe patients require hospitalization and may be divided
into those referred to a general ward or to an intensive care
unit (ICU) (Table 6). For the former, use of a second- or
third-generation cephalosporin is suggested, with the
addition of a macrolide as an option. For patients admitted
to an ICU, intravenous macrolide is recommended, with
the possible addition of rifampin and one or more anti-
pseudomonas drugs, in view of the most commonly
occurring pathogens in this setting (Fig. 1). The ATS (46)TABLE 6. Treatment of severe community-acquired pneu-
monia*,{, adapted from Mandel and Niederman (46)
Macrolideþanti-pseudomonas antibiotic
Third generation anti-pseudomonas cephalosporin,
imipenem, ciprofloxacin,
aztreonam, anti-pseudomonas penicillin
*If Legionella is identified, rifampin must be added.
{Due to the high mortality associated with P. aeruginosa
pneumonia, an aminoglycoside should be added so as to
obtain double coverage towards Pseudomonas (at least
during the first few days of treatment) when using a third-
generation cephalosporin, imipenem or ciprofloxacin.
FIG. 1. Bacteriology of severe community-acquired
pneumonia. Data from three studies (110–112).recommendations are similar to the Canadian guidelines
(45). The major difference lies in taking 60 years as the
age limit instead of 65, because American experts feel
that patients over 60 years should not be treated outside
the hospital since age becomes a co-morbidity factor in
itself.
The North American guidelines (46) recommend ery-
thromycin as first-choice antibiotic in patients under 60
years of age treated at home because of the vast experience
accumulated in the use of this drug and its relatively low
cost. However, approximately 40% of H. influenzae clinical
isolates are resistant to erythromycin (47). Moreover,
gastrointestinal disturbances and pharmacological interac-
tions following treatment with this drug are very common
and there is a high risk of poor adherence to treatment due
to significant side-effects and the need for frequent
administrations (3–4 times daily).
In smokers and in patients needing wide-spectrum
treatment, more recent macrolides such as azithromycin
and clarithromycin should, in our opinion, always be kept
in mind, also considering the high probability of H.
influenzae acting as casual pathogen (48). In many patients,
the greater cost of these macrolides is counterbalanced by
their clinical advantages and a reduced incidence of side-
effects. Both azithromycin and clarithromycin possess
better pharmacokinetic profiles and more convenient
administration schemes (49).
Even the recent guidelines by the Infectious Diseases
Society of America (IDSA) (Table 7) suggest the
empirical use of macrolides, fluoroquinolones with high
anti-S. pneumoniae activity (grepafloxacin, levofloxacin and
trovafloxacin), or doxycillin in patients that do not require
hospitalization because each of them has activity against
common pathogens as well as many atypical organisms
(50). Specifically, azithromycin and clarithromycin are to be
preferred when H. influenzae infection is suspected. In
hospitalized patients, macrolides must be associated with
b-lactams, except when bronchiectasis are present, in which
case it is preferable to add an anti-pseudomonas drug. In
serious cases of pneumonia (e.g. in the ICU), the
fluroquinolones, erythromycin, or azithromycin should be
supplemented with cefotaxime, ceftriaxone, or a b-lactam/
b-lactamase inhibitor to provide extended Gram-negative
coverage. It must be highlighted that the Food and Drug
Administration (FDA) has issued a public health advisory
to physicians concerning the risks of liver toxicity
associated with the use of trovafloxacin. This action has
followed post-marketing reports of rare but severe liver
injuries leading to transplants and deaths. Moreover,
grepafloxacin has voluntarily been withdrawn because a
small number of severe cardiovascular events (QT interval
prolongation with arrhythmias, notably torsades de pointe)
among patients has been observed.
Currently available guidelines for the treatment of CAP
are certainly useful. Adherence to the ATS guidelines
proved to be associated with improved outcome and
reduced cost of treatment. However, their use has brought
out new problems that must be evaluated with the
greatest care. For example, the use of cephalosporins has
increased considerably. This entails the risk of a selection of
TABLE 7. Empirical antibiotic selection for patients with community-acquired pneumonia according to the Infectious Diseases
Society of America guidelines (50)
Non-hospitalized patients
Generally preferred: macrolides*, fluoroquinolones{ or doxicycline
Modifying factors:
Suspected penicillin-resistant Streptococcus pneumoniae: fluoroquinolones{
Suspected aspiration: co-amoxiclav
Young adult (417–40 years): doxicycline
Hospitalized patients
General medicine ward
Generally preferred: b-lactams with or without macrolides*, or fluoroquinolones { (alone)
Alternatives: cefuroxime with or without macrolides*, or azithromycin (alone)
Admitted to Intensive Care Unit for severe pneumonia
Generally preferred: erythromycin, azithromycin or a fluoroquinoloneþcefotaxime, ceftriaxone
Alternatives: b-lactam/b-lactamase inhibitor{
Modifying factors
Structural lung disease: anti-pseudomonas penicillin, a carbapenemic, or cefepimeþa macrolide* or a fluoroquinolone {an
aminoglycoside
Allergy to penicillin: a fluoroquinolone with and without clindamycin
Suspected aspiration: a fluoroquinoloneþclindamycin or metronidazole or b-lactam/b-lactamase inhibitor {(alone)
*Azithromycin, clarithromycin or erythromycin.
{Levofloxacin, sparfloxacin, grepafloxacin or other fluoroquinolone highly active towards S. pneumoniae.
{Ampicillin/sulbactam, or ticarcillin/clavulanate or piperacillin/tazobactam (for structural lung disease, ticarcillin/clavulanate
or piperacillin).
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(51). Nonetheless, the BTS recommends the use of
cefotaxime and cefuroxime in view of concerns regarding
S. pneumoniae penicillin-resistant strains (41). However, the
current resistance rate (MIC for penicillin40?1 mgml71) in
England and Wales is as low as 3?8% (52), although
regional variations are reported. Moreover, there is no solid
evidence that these levels of resistance are clinically relevant
in pneumococcal pneumonia when adequate doses of
penicillin are administered (53). Three large S. pneumoniae
studies, enrolling a total of 41100 patients, showed no
difference in outcomes among patients infected with S.
pneumoniae that was sensitive to penicillin, had intermedi-
ate resistance to penicillin, or was highly resistant to
penicillin, but only a handful of patients had DRSP
with a MIC to penicillin of 4?0mgm71 (54–56). This
information suggests that high-dose (150 000–250 000
mg kg71 day71) penicillin are probably appropriate for
therapy in this setting. For this reason, Wort and Rogers
(57) feel there is no need for cephalosporin use as first-
choice treatment in CAP, although local epidemiological
considerations on penicillin resistance must be kept in
mind. For many British clinicians, amoxicillin and ampi-
cillin are still first-choice oral treatment (58), with co-
amoxiclav as an alternative for its greater activity towards
H. influenzae. Intravenous penicillin is restricted to severe
cases. Only if local resistance trends preclude such
treatment should cephalosporins be used.
We feel that the British approach, although scientifically
correct, is not the most effective in clinical practice. Since
the mortality rate for CAP in Italy is among the lowest in
Europe (31), we suggest that the so-called ‘Italian empiricalmodel’, according to which parenteral cephalosporins are
first-choice treatment in CAP, may be considered an
alternative good approach. This our conviction is sustained
by English language recent literature. For example, in a
recent large study, ceftazidime was shown to be highly
effective in hospitalized patients with CAP, irrespective of
the presence or absence of fundamental risk factors such as
age (465 years, male sex, serum urea 47mmol l71, serum
albumin 535 g l71 and dicult pathogens (59). However,
the authors correctly underline the need to consider risk
factors in approaching CAP. It must be remembered that
the number of elderly patients with CAP is extremely high.
In the U.K., more than 90% of patients with pneumonia
are aged over 65 years and associated mortality is
approximately 16–40% (60). For this reason, we do not
agree with Wort and Rogers’s opinion (57) that there is no
need for cephalosporins as first-line treatment in CAP.
Wesel et al. (61) compared intravenous ceftriaxone (2 g
once daily), cefotaxime (2 g three times daily), cefuroxime
(750mg three times daily, followed by 500mg orally three
times daily), and co-amoxiclav (1?2 g intravenously three
times daily, followed by 625mg orally three times daily).
Data analysis showed that ceftriaxone gave the best
probability of therapeutic success. The emerging trend in
the U.S.A. is that parenteral treatment with a cephalospor-
in (primarily ceftriaxone, or alternatively ceftazidime)
outside the hospital setting is a valid, safe, and low cost
alternative (62–64). In fact, Douglas Campbell (65) arms
that parenteral third-generation cephalosporin plus a
macrolide could be considered. Parenteral antibiotics can
now be practical options for outpatients; new infusion
pump technologies as well as new reimbursement systems
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treatment feasible.
Resistance to pneumococci in vitro is not always
accompanied by a lack of clinical response, but there are
increasing reports of treatment failures in pneumococcal
infections caused by strains with reduced susceptibility to
the drug in vitro (66,67). Resistance in pneumococci has
developed not only to penicillins, but in some strains this is
accompanied by decreased susceptibility to cephalosporins
(68,69). Macrolide resistance has also grown, with most
erythromycin-resistant strains showing cross-resistance to
other macrolides (67). Macrolide resistance is often linked
with penicillin resistance, and strains with concurrent
resistance to a number of unrelated antimicrobials (b-
lactams, macrolides, tetracyclines and co-trimoxazole) are
not uncommon (67,70). The growth of multi-resistant
pneumococci has encouraged the development of fluo-
roquinolones with improved Gram-positive activity. Sev-
eral new fluoroquinolones possess a similar range of
activity. Among those in the market, levofloxacin (71)
and moxifloxacin (72) are the most promising.
The role of the newer fluoroquinolones is also important
considering the incidence of C. pneumoniae, L. pneumophila
and Mycoplasma pneumoniae as pathogens in CAP and
their resistance to b-lactams. In fact, both levofloxacin and
moxifloxacin are active against atypical bacteria. All
guidelines suggest the addition of a macrolide. Evidence is
accumulating that new macrolides, such as clarithromycin,
are superior to erythromycin, both in terms of antibiotic
spectrum and greater activity towards C. pneumoniae (73).
We think that macrolide utility against S. pneumoniae
depends on community susceptibility and, furthermore,
macrolides are less active than levofloxacin (74) and
moxifloxacin (75) against H. influenzae, and a high
percentage of S. pneumoniae are macrolide-resistant.
In any case, a recent U.S.A. study on elderly patients
showed that the routine use of macrolides is not to be
encouraged because only 7?5% of patients presented an
organism needing macrolide treatment, and no mortality was
present among these patients (76). Woodhead (77) suggested
that a randomized, comparative controlled study should be
carried out to compare b-lactam alone with a b-lactam and a
macrolide before recommending use of a macrolide in elderly
patients with CAP because a true definition of the current
frequency with which C. pneumoniae causes CAP is lacking.
In fact, during clinical trials the presence of co-pathogens is a
common occurrence. This suggests that C. pneumoniae may
simply initiate pathological events, but a different pathogen
is the true cause of pneumonia. Therefore, it is hardly
surprising that treatment with an antibiotic ineffective
towards C. pneumoniae is equally capable of obtaining
clinical remission in approximately the same time span
obtainable following administration of an antibiotic pre-
senting activity towards this atypical pathogen (77).
However, it may be supposed that co-infection with C.
pneumoniae and other pathogens does have some effect on
the course of pneumonia. In a recent study by Kauppinen et
al. (78), three groups of patients with pneumonia were
examined: those with C. pneumoniae infection; those with S.
pneumoniae infection; and those with mixed infection. Theauthors report that in the presence of C. pneumoniae
infection alone the clinical course was mostly mild, with a
mean hospital stay of 8?4 days, although only 36% had
received adequate antibiotic treatment for this infection. In
the presence of S. pneumoniae infection, all patients had
received adequate antibiotic treatment and the mean
hospital stay was 10?5 days. However, even when both
pathogens were present, subjects were treated only for
pneumococcus and the mean hospitalization reached 21?9
days. These data suggest a possible role for co-infection in
determining increased pneumonia severity. This role seems
to be confirmed by Gordon et al. (79) who retrospectively
analysed the records of 4448 patients admitted to the
hospital, but not in the ICU, with CAP. The study found
that patients who received guideline-recommended therapy
had a significantly lower chance of dying than those
patients who received non-recommended therapy, but that
the lowest mortality rate of all was in those patients who
received both a b-lactam and a macrolide. These findings
again suggest that routine therapy directed at atypical
pathogens may be beneficial for all types of patients with
CAP.
We believe that both these findings and the documenta-
tion that C. pneumoniae has been reported to cause
pneumonia frequently in association with other micro-
organisms, mainly S. pneumoniae (80,81), support our
opinion that newer fluoroquinolones may be considered a
valid first-choice option due to their enhanced activity
against Gram-positive and atypical organisms while main-
taining activity against Gram-negative bacteria. Should
ongoing clinical trials and clinical practice demonstrate that
newer fluoroquinolones are a valid and safe monotherapy in
CAP, it is likely that future guidelines will have to keep this
class of drugs in due consideration (82). However, Campbell
(65) highlights that for hospitalized patients with mild-to-
moderate infection without DRSP risk, the recommenda-
tion is a b-lactam plus macrolide (or doxycycline) combina-
tion, or a fluoroquinolone alone (83). If there is DRSP risk,
the recommendation is cefotaxime or ceftriaxone combined
with a macrolide or a fluroquinolone alone (84).
Apart for the above considerations and the need for
changing the suggestions of guidelines according to the
evolution of pharmaceutical market that offers new and
more effective agents, we must highlight that therapeutic
recommendations contained in guidelines often clash with
factors affecting the total costs of treatment of pneumonia
such as the need for hospitalization, attempts to reach an
aetiological diagnosis, the selection of empirical antibiotic
therapy, time span needed for switching from parenteral
therapy to oral treatment and length of hospital stay.
Moreover, the management habits of single clinicians, often
reflecting local practices, must not be ignored and may
equally substantially affect the total cost of treatment. For
example, an interesting American study (85) has recently
demonstrated that the use of medical procedures and
consultations was more common for patients discharged
from University Hospitals than from general hospitals,
causing an 11% increase in costs in the former hospitals.
Similarly, costs were 15% greater in urban compared
to rural hospitals. Internal medicine and pulmonology
TABLE 8. Criteria used to identify candidates to switch from
parenteral to oral treatment. Adapted form Ramirez et al.
(107), Fine et al. (108) Ramirez (109)
Improvement in cough
Improvement in respiratory distress
Absence of fever for 424 h
Absence of high risk for resistant pathogens,
for example S. aureus
Absence of concomitant unstable medical disease
Absence of complications, for example
congestive heart failure
Intact gastrointestinal absorbance
Improvement in leucocytosis
102 M. CAZZOLA ET AL.clinicians made more use of diagnostic procedures, and on
the whole were associated with greater expenses, than
general practitioners. Notwithstanding the variability in
procedure use and treatment expenses concerning CAP,
there were no differences in mortality and in re-admission
rates.
However, one of the first and probably most important
decisions concerning cost of treatment is not the choice of
antibiotic, but rather the need for hospital admission. In
fact, with increasing pressures on healthcare resources
everywhere, the question of which patients require hospi-
talization and which do not is very pertinent. Pneumonia is
an important cause of hospital admission, but frequency
varies greatly according to the study and the clinicians
conducting the study. This suggests the need for ecient
and widely accepted predictive indices for negative out-
come. A large study involving over 50 000 patients
identified valid criteria for predicting the outcome of CAP
(86). The predictive rule allots scores based on age and the
presence of comorbidity, abnormal physical examination
(respiratory rate 430 or body temperature 4408C) and
laboratory findings (pH 57?35, serum urea 430mg dl71,
or serum sodium 5130mmol l71) on admission. Home
treatment for class I patients (no risk factors), brief
observation as inpatient for class II patients (score between
71 and 90), and hospital admission for class IV (score
between 91 and 130) and class V patients (score4130) may
significantly reduce the number of hospital admissions by
approximately one-third. However, in our opinion the
above scoring system is too complex for use in routine
clinical practice. Decreased admission rate was observed
after implementation of admission decision support in
combination with specific recommendations for outpatient
antibiotic therapy (87). Favourable outpatient outcomes
suggest that implementation of decision support was safe.
In hospitalized patients, the length of stay is a primary
determinant of the management costs of pneumonia. Data
from the National Healthcare Cost and Utilization Project,
the National Ambulatory Medical Care Survey and the
National Hospital Ambulatory Medical Care Survey were
employed to determine the cost of treatment in patients
aged 65 or over (88). Figures soared to a total cost of $U.S.
4?8 billion for the treatment of patients aged over 65, and
over $U.S. 3?6 billion for the treatment of patients aged
under 65 years. The mean length of hospital stay was 7?8 days
with a mean cost of $U.S. 7166 for patients over 65, and 5?8
days with a mean cost of $U.S. 6042 for younger patients.
Obviously, given the high cost of CAP requiring
hospitalization, every treatment that allows home manage-
ment may result in substantial savings, particularly among
patients under 65 years of age.
One of the key elements determining length of hospital
stay is the duration of parenteral antibiotic treatment.
Ehrenkranz et al. (89) reported a reduction in mean
hospital stay by 2?4 days and a $U.S. 884 reduction per
patient/therapy when parenteral treatment was switched
to oral treatment and the patient was discharged on the
third day of hospitalization. It is interesting to note that in
this study the disease severity indices and the outcome
following discharge were similar for those inpatients whohad continued parenteral treatment and prolonged hospital
stay. Generally, by cautiously applying specific criteria for
the identification of candidates for switch therapy (Table 8),
most patients may be treated orally within 3 days from
initiation of therapy.
By altering the prescribing habits of hospital-based
clinicians in CAP, it may be possible to lower costs with
no significant increase in the risk of negative outcome.
Proof of this is found in the study by Omidvari et al. (90).
The authors treated a group of patients with cefamandol
1 g intravenously every 6 h for 7 days, and a second group
with cefamandol (1 g intravenously every 6 h for 2 days)
followed by oral treatment with cefaclor (500mg every 8 h
for 5 days). Between the two groups there was no difference
in clinical course, remission rate, survival rate and clearing
of radiographic abnormalities. Average length of treatment
(6?88 days for the conventional group compared to 7?30
days for the group with switch therapy), and the rate of
overall symptom improvement (97% vs. 95%, respectively)
was similar in both groups. Patients receiving precocious
oral treatment required a shorter hospital stay (7?3 vs.
9?71 days, P=0?01), and overall expenses were lower
($U.S. 2953 vs. $U.S. 5002, P50?05).
Although only the ISDA guidelines highlight that
patients can usually be switched from i.v. to oral therapy
within 3 days, provided a good oral antibiotic is available
and that the patient is in clinically stable condition and can
tolerate the drug (50), we believe that this action is
extremely important and useful. In fact, the early hospital
discharge associated with switch therapy will decrease the
patients’s risk for nosocomial infections such as urinary or
respiratory tract infections. Moreover, switch therapy is
associated with a clinical cure rate that is equivalent to
conventional therapy. In the era of cost-effective use of
antibiotics, switch therapy should be considered as one of
the primary options for healthcare cost containment.
Nosocomial pneumonia guidelines
The aetiology of nosocomial pneumonia (NP) is substan-
tially different from that of CAP, which explains the need
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aeruginosa, Klebsiella, Acinetobacter spp., Enterobacter and
Gram-positive cocci such as S. aureus are common causes
of nosocomial pneumonia (91,92). In particular, it has been
demonstrated that early-onset NP (i.e. occurring within
48–96 h of ICU admission) is most often reported to be due
to antibiotic-sensitive pathogens including H. influenzae,
oxacillin-sensitive S. aureus and S. pneumoniae, while late-
onset NP (i.e. occurring 448–96 h after ICU admission) is
frequently attributed to antibiotic-resistant pathogens such
oxacillin-resistant S. aureus, P. aeruginosa, Acinetobacter
spp. and Enterobacter spp., (93,94) although antibiotic-
resistant pathogens can also be isolated in early-onset NP
patients (95). Disease caused by these virulent pathogens is
often severe and commonly complicated by pulmonary
necrosis, multi-lobar involvement, micro-abscesses or em-
pyema. Mortality attributable to NP is significant in most
patient populations and prompt administration of appro-
priate empiric antibiotic therapy in these groups is
associated with improved outcomes (96,97).
Guidelines on NP are relatively scarce. Except for U.S.A.
and Canadian guidelines, the only other national recom-
mendations appear in Australia, Sweden and France (98).
However, due to the lack of useful data for the drawing up
of guidelines based on clinical evidence, it is probably more
appropriate to refer to these documents as consensus
among experts rather than true guidelines.
Specifically, the ATS (Table 9) recommends that
antibiotic choice should take into account disease severity,
length of hospital stay and the presence of specific risk
factors (99). When pneumonia arises within 5 days from
hospitalization, a b-lactam/b-lactamase inhibitor or a
second- or third-generation cephalosporin is recommended.
When pneumonia arises later during hospital stay, it is
imperative that antibiotics active against P. aeruginosa
be used, such as the association between an amino-
glycoside or a fluoroquinolone and a wide spectrum
b-lactam. When anaerobic infection is present, clindamycin
or an association b-lactam/b-lactamase inhibitor is sug-
gested, whereas vancomycin is recommended when methi-
cillin-resistant S. aureus is suspected. Conversely, when
Legionella infection is suspectable a macrolide should be
used (100).
Unfortunately, the ATS therapeutic recommendations
for early-onset NP would result in under-treating patients
who are infected with oxacillin-resistant S. aureus or
P. aeruginosa. The antimicrobial recommendations for
patients who develop late-onset NP should also apply to
patients with early-onset NP when significant rates of early-
onset NP are demonstrated to be due to potentially
antibiotic-resistant bacteria (95). Such pathogens should
most commonly be observed in patients with risk factors
for infection due to antibiotic-resistant bacteria including
prior antibiotic therapy and prolonged mechanical ventila-
tion (93).
It is important to underline that several studies demon-
strate that all treatment approaches suggested by the
different guidelines are ineffective in up to 30–40% of cases
(101,102). The presence of unresponsive pathogens is the
main cause of treatment failures. These may be commonNP pathogens that develop in unexpected environments or
with unusual resistance patterns. Prevalence of particular
nosocomial pathogens and prevailing antibiotic resistance
levels vary from one hospital to another, depending on
many factors. In most hospitals, effective empirical therapy
will require activity against Gram-negative bacilli, espe-
cially Pseudomonas and Acinetobacter, as well as Gram-
positive organisms. Thus, at least initially, multi-drug
therapy will be required (103). Many authors feel that
two-drug regimens are insucient to reduce the incidence
of bacteria not covered by antibiotic therapy (104).
It must be remembered that when using empirical
antibiotic treatment in a hospital ward, unresponsive
patients must be quickly identified and alternative treat-
ment schemes must be available. Treatment may require
modifications on the basis of patient culture results and/or
clinical response. The latter may be dicult to assess due to
the variable course of NP, and is also associated with host
and bacterial factors and the co-existence of other
pathological processes.
Deplorably, currently available guidelines do not suggest
reliable alternatives, but rather consider risk factors and the
severity of the disease, with little attention being brought to
previously mentioned aspects. As a result, we think the best
way to treat patients with NP is to prescribe a therapy with
three antibiotics with different spectrums and mechanisms
of action, and to narrow the treatment as soon as
microbiological data are available. We know that this
approach is expensive and might elicit resistance, but we
also know that an inappropriate therapy can induce the
death of our patient.
Conclusions
The present critical evaluation of existing guidelines on the
treatment of lower respiratory tract infections shows the
great effort displayed in optimizing therapeutical approach.
However, the fundamental debate on the possibility that
current guidelines may induce changes in prescribing habits
is as yet unresolved.
We feel that guidelines will be effective and will improve
management quality, with a clear-cut reduction in expenses,
only when the concept that empirical therapy in the absence
of diagnostic tests is effective has been validated by
fulfilment of all adequate end points.
Clearly, the selection of drugs to be inserted in guidelines
must not be based solely on drug selling prices. This clashes
with the conclusions of a solid Canadian study conducted
to determine variations in antibiotic use, expense of
antibiotic treatment, and clinical outcome of patients
according to the institution in which the patient was
treated (105). This study not only showed that wide
variations in prescribing habits between different institu-
tions caused significant variations in expenses, but also
demonstrated that patients treated in institutions with low
antibacterial treatment costs did not present worse clinical
outcomes.
Nonetheless, we feel that antibiotics with the lowest
selling price may not necessarily be the best choice on the
TABLE 9. Organisms associated with nosocomial pneumonia and antibiotics recommended by the American Thoracic
Society guidelines (99)
Group 1: mild-to-moderate nosocomial pneumonia, no unusual risk factors, onset at any moment, or early-onset severe
nosocomial pneumonia
Key organisms* Key antibiotics
Enteric Gram-negative
bacteria (non-Pseudomonas
such as: Enterobacter,
Escherichia coli, Proteus,
Klebsiella, Serratia
marcescens, Haemophilus
influenzae
Methicillin susceptible
Staphylococcus aureus
Streptococcus pneumoniae
Cephalosporin (second- or third-
generation, non-anti-
pseudomonas) or
b-lactam/b-lactamase inhibitor or
if allergic to penicillin, a
fluoroquinolone{ or
clindamycinþaztreonam
Group 2: mild-to-moderate nosocomial pneumonia with risk factors associated with specific additional organisms, onset in
any moment
Risk factors Key organismsþspecific risk
organisms*
Key antibioticsþspecific
additional coverage
Abdominal surgery, aspiration Anaerobes Clindamycin, or b-lactam/b-lactamase
inhibitor
Coma, cranial trauma,
diabetes, renal failure
S. aureus +vancomycin (until MRSA is
not excluded)
High-dose steroids Legionella Erythromycin+rifampin
Prolonged stay in intensive
care, steroids, antibiotics,
pulmonary disease
Pseudomonas aeruginosa Treat as severe nosocomial
pneumonia (group 3)
Group 3: severe nosocomial pneumonia with risk factors, early onset, or severe nosocomial pneumonia, late onset
Key organisms* Antibiotics
Pseudomonas aeruginosa Aminoglycoside or ciprofloxacinþ
Acinetobacter spp.
Consider MRSA
one of the following:
anti-pseudomonas penicillin,
b-lactam/b-lactamase inhibitor and
+vancomycin (if MRSA is a
problem)
*Recommended treatment does not include immunocompromized patients.
{If S. pneumoniae is not a problem.
MRSA: methicillin-resistant S. aureus.
104 M. CAZZOLA ET AL.basis of the cost-effectiveness ratio, particularly considering
factors that condition health expenses. At least three
outcomes are relevant in the management of lower
respiratory tract infection: effects on the patient, those onbacteria and economical aspects. Therefore attention must
not be limited to drug costs.
Considering economical endpoints, attention to resource
employment is essential. Hospital administrations focus
GUIDELINES FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS 105attention on the length of stay and the degree of
reimbursement from health authorities. For this reason,
management of lower respiratory tract infection cases must
be shifted to less expensive environments, therefore dismiss-
ing the patient as soon as possible. A further, often ignored
endpoint, is the economical prospective of the patient (e.g.
patient’s inability to work and consequent loss in salary).
Only short effective treatment may give satisfactory answers
to this last problem. Therefore, it must always be kept in
mind that economical effects have driven, and will continue
to drive, patient treatment. On the basis of all aspects
mentioned above, the utility of guidelines for the treatment
of lower respiratory tract infections becomes apparent.
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